Targets for Liver Injury
Drug R&D Solutions

Targets for Liver Injury

Inquiry

Understanding the molecular targets implicated in Liver Injury is critical for elucidating the complex pathogenic mechanisms underlying hepatocellular damage, inflammation, and fibrogenesis. The targets identified here are primarily involved in immune cell recruitment, inflammatory signaling, oxidative stress responses, cell death, and tissue remodeling—processes central to both acute and chronic liver injury. Chemokines such as CCL5 and CX3CL1 mediate leukocyte infiltration, while cytokines like IL1B drive inflammatory cascades. Key signaling molecules (JAK1, JAK2, MAP3K5) and transcriptional regulators (NFE2L2, KEAP1, CREBBP, EP300) orchestrate cellular responses to injury, including survival, apoptosis, and antioxidant defense. Enzymes such as HDAC6 and ENPP2 modulate epigenetic and lipid signaling pathways, respectively, influencing fibrosis and regeneration. This integrated understanding of disease-relevant targets supports the identification of therapeutic intervention points, enables the development of targeted drugs, and informs biomarker discovery for diagnosis and prognosis. Collectively, these targets provide a molecular framework for dissecting disease progression, stratifying patients, and designing rational, mechanism-based therapies for Liver Injury.

Inflammatory Mediators And Immune Cell Recruitment

This category includes chemokines and cytokines that directly mediate immune cell recruitment and inflammatory amplification in liver injury. They are pivotal in initiating and sustaining hepatic inflammation, a hallmark of both acute and chronic liver damage. The targets in this group are C-C motif chemokine ligand 5 (CCL5), C-X3-C motif chemokine ligand 1 (CX3CL1), and Interleukin 1 beta (IL1B). Their collective action orchestrates the infiltration and activation of monocytes, neutrophils, and lymphocytes within the liver parenchyma, contributing to hepatocellular injury, necrosis, and progression to fibrosis.

C-C motif chemokine ligand 5 (CCL5)

CCL5 is a chemokine that plays a central role in recruiting T cells, eosinophils, and monocytes to sites of liver injury. Structurally, it is a small secreted protein with a typical chemokine fold stabilized by disulfide bonds. CCL5 is transcriptionally regulated by NF-κB and other inflammatory signals. In liver injury, CCL5 is upregulated in hepatocytes, Kupffer cells, and hepatic stellate cells, promoting infiltration of inflammatory cells (PMID: 18360152). Its pathogenic role is supported by animal models where CCL5 deficiency or antagonism reduces hepatic inflammation and fibrosis. Therapeutically, CCR5 antagonists (e.g., Maraviroc) are under investigation for liver disease. CCL5 is a potential biomarker and therapeutic target for attenuating immune-mediated hepatic injury.

C-X3-C motif chemokine ligand 1 (CX3CL1)

CX3CL1, also known as fractalkine, is a unique chemokine that exists in both membrane-bound and soluble forms, facilitating firm adhesion and chemotaxis of monocytes and cytotoxic lymphocytes. It contains a chemokine domain followed by a mucin-like stalk. In liver injury, CX3CL1 is expressed by endothelial and epithelial cells, guiding inflammatory cell migration to the liver (PMID: 22583415). Its receptor, CX3CR1, is expressed on monocytes and NK cells. CX3CL1/CX3CR1 signaling enhances hepatic inflammation and has been implicated in the progression of nonalcoholic steatohepatitis (NASH). Targeting this axis reduces inflammation and fibrosis in preclinical models, making it a promising therapeutic target.

Interleukin 1 beta (IL1B)

IL1B is a pro-inflammatory cytokine produced as an inactive precursor and processed by the inflammasome/caspase-1 complex. It contains a β-trefoil structure typical of IL-1 family members. IL1B is upregulated in response to hepatic injury and amplifies inflammation by inducing chemokines, adhesion molecules, and secondary cytokines (PMID: 22274820). It promotes hepatocyte apoptosis and activates hepatic stellate cells, contributing to fibrosis. IL1B blockade has shown efficacy in reducing liver inflammation and fibrosis in animal models. IL1B is a validated biomarker and a target for anti-inflammatory therapies (e.g., anakinra) in liver disease.

Inflammatory Signal Transduction And Transcriptional Regulation

This category encompasses kinases and transcriptional regulators that modulate the magnitude and duration of inflammatory signaling in liver injury. These targets are critical for integrating extracellular inflammatory cues into nuclear responses that determine cell fate, cytokine production, and stress adaptation. Included are Janus kinase 1 (JAK1), Janus kinase 2 (JAK2), Mitogen-activated protein kinase kinase kinase 5 (MAP3K5), and transcriptional coactivators CREB binding protein (CREBBP) and E1A binding protein p300 (EP300). These molecules influence the JAK/STAT, MAPK, and NF-κB pathways, which are central to liver inflammation, apoptosis, and regeneration.

Janus kinase 1 (JAK1)

JAK1 is a non-receptor tyrosine kinase with a FERM, SH2, and kinase domain. It is activated by cytokine receptors including those for IL6 and interferons. Upon activation, JAK1 phosphorylates STAT proteins, driving transcription of pro-inflammatory and pro-fibrotic genes (PMID: 31972145). In liver injury, JAK1 mediates cytokine-driven inflammation and hepatocyte apoptosis. Inhibition of JAK1 reduces liver inflammation and fibrosis in preclinical models. JAK inhibitors (e.g., baricitinib) are being evaluated for liver inflammatory diseases. JAK1 is a potential biomarker for pathway activation.

Janus kinase 2 (JAK2)

JAK2 shares structural features with JAK1 and is similarly activated by cytokine receptors. It is particularly important for IL6 and interferon-γ signaling, which are elevated in liver injury. JAK2 activation promotes STAT3 phosphorylation, driving expression of acute-phase proteins and apoptosis regulators (PMID: 29342129). JAK2 inhibition ameliorates liver inflammation and fibrosis in animal models. JAK2 is a therapeutic target and a marker of inflammatory signaling in hepatic disease.

Mitogen-activated protein kinase kinase kinase 5 (MAP3K5)

MAP3K5 (ASK1) is a serine/threonine kinase with a kinase domain and regulatory regions. It is activated by oxidative stress and TNF-α, leading to phosphorylation of downstream kinases (MKK4/7, MKK3/6) in the JNK and p38 MAPK pathways. MAP3K5 promotes hepatocyte apoptosis and inflammation (PMID: 18287608). Genetic or pharmacological inhibition of MAP3K5 protects against liver injury in models of NASH and fibrosis. MAP3K5 is a validated drug target (e.g., selonsertib) in clinical trials for liver fibrosis.

CREB binding protein (CREBBP)

CREBBP is a transcriptional coactivator with histone acetyltransferase (HAT) activity, bromodomain, and multiple protein interaction motifs. It acetylates histones and transcription factors (e.g., NF-κB, p53), facilitating the transcription of inflammatory and survival genes. In liver injury, CREBBP is required for the expression of genes involved in inflammation and regeneration (PMID: 15496404). Dysregulation of CREBBP activity exacerbates inflammation and impairs tissue repair. Targeting CREBBP HAT activity is an emerging strategy for modulating hepatic inflammation.

E1A binding protein p300 (EP300)

EP300 is a paralog of CREBBP with similar domain architecture and functions. It acts as a HAT and coactivator for transcription factors involved in inflammation and cell cycle regulation. EP300 is upregulated in liver injury and is essential for the transcription of acute-phase and fibrogenic genes (PMID: 24607936). Inhibition of EP300 reduces hepatic inflammation and fibrosis in preclinical models. EP300 is a candidate therapeutic target for modulating liver disease progression.

Oxidative Stress Response And Antioxidant Defense

This category includes targets that regulate the hepatic response to oxidative stress, a key driver of hepatocellular injury and fibrosis. The NFE2 like bZIP transcription factor 2 (NFE2L2, or NRF2) and Kelch like ECH associated protein 1 (KEAP1) form a regulatory axis that controls the expression of antioxidant and cytoprotective genes. Their balance determines the cellular capacity to detoxify reactive oxygen species (ROS) generated during liver injury.

NFE2 like bZIP transcription factor 2 (NFE2L2)

NFE2L2 (NRF2) is a transcription factor with a bZIP domain, regulating genes with antioxidant response elements (ARE). Under basal conditions, NRF2 is sequestered in the cytoplasm by KEAP1, which targets it for ubiquitination. Upon oxidative stress, NRF2 escapes KEAP1 and translocates to the nucleus, inducing expression of detoxifying enzymes (e.g., GCLC, NQO1). In liver injury, NRF2 activation protects against oxidative damage and fibrosis (PMID: 22968403). NRF2 activators attenuate liver injury in preclinical models. NRF2 is a validated target and biomarker for oxidative stress response.

Kelch like ECH associated protein 1 (KEAP1)

KEAP1 is a cytoplasmic repressor of NRF2, containing BTB, IVR, and Kelch domains. It senses electrophilic and oxidative stress via cysteine residues, releasing NRF2 to allow its nuclear translocation. KEAP1 mutations or inhibition lead to constitutive NRF2 activation. In liver injury, KEAP1 dysregulation impairs antioxidant defense, increasing susceptibility to oxidative damage (PMID: 22968403). KEAP1 is an indirect therapeutic target; small molecules that disrupt KEAP1-NRF2 interaction enhance hepatic resilience to injury.

Epigenetic And Post-Translational Modifiers

This category includes enzymes that regulate chromatin structure and protein function through acetylation and deacetylation, thereby influencing gene expression and cellular responses in liver injury. Histone deacetylase 6 (HDAC6) is a key member, modulating the acetylation status of both histones and non-histone proteins, impacting inflammation, cell death, and fibrogenesis.

Histone deacetylase 6 (HDAC6)

HDAC6 is a cytoplasmic deacetylase with two catalytic domains and a ubiquitin-binding zinc finger. It deacetylates α-tubulin, HSP90, and cortactin, regulating cytoskeletal dynamics, autophagy, and stress responses. In liver injury, HDAC6 is upregulated and promotes inflammation, oxidative stress, and hepatic stellate cell activation (PMID: 28432130). Inhibition of HDAC6 reduces liver injury and fibrosis in animal models. HDAC6 inhibitors (e.g., tubastatin A) are being explored for hepatoprotective effects. HDAC6 is a candidate biomarker and therapeutic target.

Cell Death And Fibrosis Modulators

This category includes enzymes involved in lipid signaling and cell death that modulate the fibrogenic response to liver injury. Ectonucleotide pyrophosphatase/phosphodiesterase 2 (ENPP2) and Pannexin 1 (PANX1) are implicated in hepatic fibrosis, inflammation, and cell death pathways.

Ectonucleotide pyrophosphatase/phosphodiesterase 2 (ENPP2)

ENPP2 (autotaxin) is a secreted lysophospholipase D with a catalytic domain that converts lysophosphatidylcholine to lysophosphatidic acid (LPA). LPA signaling promotes hepatic stellate cell activation, fibrosis, and inflammation (PMID: 25650345). ENPP2 is upregulated in liver injury and correlates with fibrosis severity. Pharmacological inhibition of ENPP2 reduces fibrosis in animal models. ENPP2 is a biomarker and target for anti-fibrotic therapy.

Pannexin 1 (PANX1)

PANX1 is a membrane channel protein with four transmembrane domains, forming large-pore channels for ATP release. In liver injury, PANX1-mediated ATP release triggers inflammasome activation, immune cell recruitment, and hepatocyte death (PMID: 32042182). PANX1 inhibition reduces liver inflammation and cell death in preclinical models. PANX1 is a potential therapeutic target for limiting sterile inflammation in liver injury.

Name Short Name Entrez Gene KEGG UniProtKB
C-C motif chemokine ligand 5 CCL5 6352 6352 P13501
C-X3-C motif chemokine ligand 1 CX3CL1 6376 6376 P78423
CDC like kinase 1 CLK1 1195 1195 P49759
CDC like kinase 2 CLK2 1196 1196 P49760
CREB binding protein CREBBP 1387 1387 Q92793
E1A binding protein p300 EP300 2033 2033 Q09472; A0A669KB12
ectonucleotide pyrophosphatase/phosphodiesterase 2 ENPP2 5168 5168 Q13822
egl-9 family hypoxia inducible factor 1 EGLN1 54583 54583 Q9GZT9
histone deacetylase 6 HDAC6 10013 10013 Q9UBN7
interleukin 1 beta IL1B 3553 3553 P01584
Janus kinase 1 JAK1 3716 3716 P23458
Janus kinase 2 JAK2 3717 3717 O60674
kelch like ECH associated protein 1 KEAP1 9817 9817 Q14145
mitogen-activated protein kinase kinase kinase 5 MAP3K5 4217 4217 Q99683
NFE2 like bZIP transcription factor 2 NFE2L2 4780 4780 Q16236
nuclear receptor subfamily 1 group H member 4 NR1H4 9971 9971 Q96RI1
pannexin 1 PANX1 24145 24145 Q96RD7
HOW WE WORK

Make Order

Make Order

Experimental Scheme

Experimental Scheme

Implementation

Implementation

Conclusion

Conclusion
Make an Inquiry